Prognostic role of salivary CD44sol levels in the follow-up of laryngeal carcinomas

Journal of Oral Pathology and Medicine

Volumn 43, Issue 4, 2014, Pages 276-281

  Allegra, Eugenia ^a   Trapasso, Serena ^a   La Boria, Alessandro ^a   Aragona, Teodoro ^a   Pisani, Davide ^a   Belfiore, Antonino ^a   Garozzo, Aldo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

ELISA; Head and neck squamous cell carcinoma (HNSCC); Prognostic factor; Saliva; Soluble CD44 (CD44sol)

Indexed keywords

SALIVARY SOLUBLE CD44; TUMOR MARKER; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; HERMES ANTIGEN;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEAD AND NECK DISEASE; HISTOPATHOLOGY; HUMAN; LARYNX CARCINOMA; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADULT; CARCINOMA; CHEMISTRY; COMPARATIVE STUDY; DRINKING BEHAVIOR; HEAD AND NECK TUMOR; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MIDDLE AGED; NECK DISSECTION; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SALIVA; SECONDARY; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR RECURRENCE;

ADULT; AGED; ALCOHOL DRINKING; ANTIGENS, CD44; CARCINOMA; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SALIVA; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84898057010     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12129     Document Type: Article

References (30)

1. Garozzo A, Allegra E, La Boria A, Lombardo N. Modified supracricoid laryngectomy. Otolaryngol Head Neck Surgery 2010; 141: 137-9.
2. Allegra E, Lombardo N, La Boria A, et al. Quality of voice evaluation in patients treated by supracricoid laryngectomy and modified supracricoid laryngectomy. Otolaryngol Head Neck Surg 2011; 145: 789-95.
3. Allegra E, Franco T, Trapasso S, Aragona T, Domanico R, Garozzo A. Quality of life in patients treated by organ preservation surgery for early laryngeal carcinoma. Open Access Surg 2012a; 2012: 27-32.
4. Allegra E, Franco T, Trapasso S, Domanico R, La Boria A, Garozzo A. Modified supracricoid laryngectomy: oncological and functional outcomes in the elderly. Clin Interv Aging 2012b; 7: 475-80.
5. Spector JG, Sessions DG, Haughey BH, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 2001; 111: 1079-87.
6. Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer 2012; 106: 846-53.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
8. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
9. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
10. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-63.
11. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
12. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-33.
13. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-8.
14. Trapasso S, Allegra E. Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biologics 2012; 6: 379-83.
15. Allegra E, Trapasso S. Cancer stem cells in head and neck cancer. Onco Targets Ther 2012; 5: 375-83.
16. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39: 527-79.
17. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
18. Biddle A, Liang X, Gammon L, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011; 71: 5317-26.
19. Guo YJ, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994; 54: 422-6.
20. van Hal NL, van Dongen GA, ten Brink CB, et al. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res 1999; 5: 3534-41.
21. Allegra E, Trapasso S, Sacco A, Aragona T, Belfiore A, Garozzo A. Elisa detection of salivary levels of CD44sol as a diagnostic test for laryngeal carcinomas. J Cancer Sci Ther 2012c; 4: 330-4.
22. Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 735-9.
23. Franzmann EJ, Reategui EP, Pedroso F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1348-55.
24. Franzmann EJ, Reategui EP, Pereira LH, et al. Salivary protein and CD44sol levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck 2012; 34: 687-95.
25. Brandwein-Gensler M, Smith RV. Prognostic indicators in head and neck oncology including the new 7th edition of theAJCC staging system. Head Neck Pathol 2010; 4: 53-61.
26. Allegra E, Caltabiano R, Amorosi A, Vasquez E, Garozzo A, Puzzo L. Expression of BMI1 and p16 in laryngeal squamous cell carcinoma. Head Neck 2013; 35: 847-51.
27. Allegra E, Puzzo L, Zuccalà V, et al. Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status. World J Surg Oncol 2012d; 10: 206.
28. Yüce I, Bayram A, Caǧli S, Canöz O, Bayram S, Güney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol 2011; 32: 141-146.
29. de Jong MC, Pramana J, van der Wal JE, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010; 16: 5329-38.
30. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009; 119: 1518-30.